Only in Titles

Search results for: antibody

paperclip

#35961779   2022/08/12 To Up

Efficacy of SARS-CoV-2 vaccination in patients with monoclonal gammopathies: A cross sectional study.

SARS-CoV-2 vaccination is the most effective strategy to protect individuals with haematologic malignancies against severe COVID-19, while eliciting limited vaccine responses. We characterized the humoral responses following 3 mo after mRNA-based vaccines in individuals at different plasma-cell disease stages: monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), and multiple myeloma on first-line therapy (MM), compared with a healthy population. Plasma samples from uninfected MM patients showed lower SARS-CoV-2-specific antibody levels and neutralization capacity compared with MGUS, SMM, and healthy individuals. Importantly, COVID-19 recovered MM individuals presented significantly higher plasma neutralization capacity compared with their uninfected counterparts, highlighting that hybrid immunity elicit stronger immunity even in this immunocompromised population. No differences in the vaccine-induced humoral responses were observed between uninfected MGUS, SMM and healthy individuals. In conclusion, MGUS and SMM patients could be SARS-CoV-2 vaccinated following the vaccine recommendations for the general population, whereas a tailored monitoring of the vaccine-induced immune responses should be considered in uninfected MM patients.
Eugenia Abella, Macedonia Trigueros, Edwards Pradenas, Francisco Muñoz-Lopez, Francesc Garcia-Pallarols, Randa Ben Azaiz Ben Lahsen, Benjamin Trinité, Victor Urrea, Silvia Marfil, Carla Rovirosa, Teresa Puig, Eulàlia Grau, Anna Chamorro, Ruth Toledo, Marta Font, Dolors Palacín, Francesc Lopez-Segui, Jorge Carrillo, Nuria Prat, Lourdes Mateu, Bonaventura Clotet, Julià Blanco, Marta Massanella,

1318 related Products with: Efficacy of SARS-CoV-2 vaccination in patients with monoclonal gammopathies: A cross sectional study.

100 ul100 ul100.00 ug100 ul100ug10 mg100ug25ug100100.00 ug100 μg100.00 ug

Related Pathways

paperclip

#35961708   2022/02/18 To Up

Immunotherapy for hepatobiliary cancers: Emerging targets and translational advances.

Over the past several decades, primary liver cancer (PLC), mostly hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (iCCA), has become the focus of rising concern mainly due to the increasing rates of incidence and high global mortality. Immunotherapy, as an emerging treatment approach, represents an effective and promising option against PLC. However, the selection of immunotherapeutic targets while considering tumor heterogeneity and immunosuppressive tumor microenvironment is a major challenge. The purpose of this review is to summarize and present the emerging immunotherapeutic targets for HCC and iCCA and to evaluate their translation advances in currently ongoing clinical trials. To better provide a framework for the liver cancer target selection, this chapter will highlight cell surface antigens expressed in both tumor cells and immune cells. Particular focus will be on the development, biology and function of Glypican-3 (GPC3) and Mesothelin (MSLN) in the cancer progress of HCC and iCCA, respectively. By doing so, we will explore the prospects and applications of various immunotherapeutic strategies such as vaccines, monoclonal antibodies, immunotoxins, antibody-drug conjugates (ADCs) and chimeric antigen receptors (CARs) T cells that have been developed targeting GPC3 and MSLN.
Dan Li, Shaoli Lin, Jessica Hong, Mitchell Ho

2067 related Products with: Immunotherapy for hepatobiliary cancers: Emerging targets and translational advances.

50 mg250 mg0.1 ml25 mg100ul5 mg2.5 mg100ug96T100ul100ug

Related Pathways

paperclip

#35961687   2022/08/12 To Up

Case of idiopathic multicentric Castleman's disease: the master mimicker.

A
Larabe Farrukh, Andrea Lightle, Ruben Peredo-Wende, Shannon Murawski

2789 related Products with: Case of idiopathic multicentric Castleman's disease: the master mimicker.



Related Pathways

    No related Items
paperclip

#35961566   2022/08/09 To Up

Impact of various factors on the kinetics of non-enzymatic fragmentation of a monoclonal antibody.

Non-enzymatic hinge fragmentation of monoclonal antibodies (mAb) is considered a critical quality attribute since it changes the primary sequence of the proteins, thereby leading to structural changes which can affect stability, function, and efficacy. While peptide bonds are exceptionally stable under physiological conditions, reactive side chains of a few residues, the flexibility of the backbone, and physicochemical parameters such as pH, temperature, and the reaction of radicals and metal ions can promote the cleavage of peptide bonds. In this study, the relative extent and rate of fragmentation are compared with respect to the presence of several different factors (including hydrogen peroxide, metal ion, and temperature) as measured by size exclusion chromatography. A kinetic model of monomer degradation as a function of time (mAb only) is created. In the presence of either HO or Cu, or both, the reaction kinetics follow different orders depending on the reaction conditions. The half-life for peptide bond cleavage of the mAb hinge region was 385 days at 40 °C and decreases to 250, 48, and 45 days in the presence of HO, Cu, and a combination of HO and Cu, respectively. A temperature dependence of peptide bond cleavage at 35 °C, 40 °C, 45 °C, and 50 °C showed Arrhenius behavior with an apparent activation energy of 76.9±16.4 kJ/mol. The reaction rates obtained from the Arrhenius equation were then extrapolated to predict fragmentation rates under real storage conditions (e.g., at 2-8 °C). We demonstrate that trace levels of impurities including peroxide left after surface sterilization or degradation of non-ionic surfactants or metal ions from the buffer components can significantly affect the stability of a mAb.
Surbhi Gupta, Kratika Upadhyay, Christian Schöneich, Anurag S Rathore

2229 related Products with: Impact of various factors on the kinetics of non-enzymatic fragmentation of a monoclonal antibody.